Monograph

J07BF03 - Poliomyelitis, Trivalent, Inactivated, Whole Virus

Propably not porphyrinogenic

Rationale

Based on the pharmacokinetics of the poliomyelitis, trivalent, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.

Chemical description

Inactivated polio virus type 1, 2 and 3.

Therapeutic characteristics

The poliomyelitis vaccine is indicated for the active immunization against poliomyelitis in infants, children and adults, for both primary immunization (2 or 3 doses) and for following booster doses. It is administered by intramuscular or deep subcutaneous injection.

Metabolism and pharmacokinetics

The poliomyelitis vaccine is not metabolized by the cytochrome P450 system.

References

#	Citation details	PMID
*	Government bodies
1.	Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
*	Summary of Product Characteristics
2.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Imovax Polio. (Last edition: 31.06. 2014).

Citation details

PMID

Government bodies

Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Imovax Polio. (Last edition: 31.06. 2014).

Similar drugs

Explore alternative drugs in similar therapeutic classes J07B / J07BF or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands